Post-marketing surveillance demonstrates low adverse events and effective prevention of reflux esophagitis recurrence in Japan, indicating a beneficial treatment option.
This study demonstrates the effectiveness of vonoprazan in preventing RE recurrence during maintenance treatment in clinical practice. The incidence of ADRs was low, and no new safety signals were identified, supporting the established safety profile of vonoprazan.Clinical trial registration: NCT03214081; jRCT1080223147.
No takes yet. Share an insight, caveat, or question.
Manabe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: